View in EDS HTML Full Text PDF Full Text

Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.

Saved in:
Bibliographic Details
Title: Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.
Authors: Alcalá C; Department of Neurology, La Fe Hospital, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain. mc.alcalavicente@gmail.com., Gascón F; Department of Neurology, Clinic Hospital, Valencia, Spain., Pérez-Miralles F; Department of Neurology, La Fe Hospital, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain., Domínguez JA; Department of Neurology, Clinic Hospital, Valencia, Spain., Gil-Perotín S; Department of Neurology, La Fe Hospital, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain., Casanova B; Department of Neurology, La Fe Hospital, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain.
Source: Journal of neurology [J Neurol] 2019 Mar; Vol. 266 (3), pp. 726-734. Date of Electronic Publication: 2019 Jan 19.
Publication Type: Journal Article; Observational Study
Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0423161 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1459 (Electronic) Linking ISSN: 03405354 NLM ISO Abbreviation: J Neurol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 30661133
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Alcalá+C%22">Alcalá C</searchLink>; Department of Neurology, La Fe Hospital, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain. mc.alcalavicente@gmail.com.<br /><searchLink fieldCode="AU" term="%22Gascón+F%22">Gascón F</searchLink>; Department of Neurology, Clinic Hospital, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Pérez-Miralles+F%22">Pérez-Miralles F</searchLink>; Department of Neurology, La Fe Hospital, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Domínguez+JA%22">Domínguez JA</searchLink>; Department of Neurology, Clinic Hospital, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Gil-Perotín+S%22">Gil-Perotín S</searchLink>; Department of Neurology, La Fe Hospital, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain.<br /><searchLink fieldCode="AU" term="%22Casanova+B%22">Casanova B</searchLink>; Department of Neurology, La Fe Hospital, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220423161%22">Journal of neurology</searchLink> [J Neurol] 2019 Mar; Vol. 266 (3), pp. 726-734. <i>Date of Electronic Publication: </i>2019 Jan 19.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Observational Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer-Verlag%22">Springer-Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>0423161 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-1459 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203405354%22">03405354 </searchLink><i>NLM ISO Abbreviation: </i>J Neurol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=30661133
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00415-019-09195-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 726
    Titles:
      – TitleFull: Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Alcalá C
      – PersonEntity:
          Name:
            NameFull: Gascón F
      – PersonEntity:
          Name:
            NameFull: Pérez-Miralles F
      – PersonEntity:
          Name:
            NameFull: Domínguez JA
      – PersonEntity:
          Name:
            NameFull: Gil-Perotín S
      – PersonEntity:
          Name:
            NameFull: Casanova B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2019 Mar
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-electronic
              Value: 1432-1459
          Numbering:
            – Type: volume
              Value: 266
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Journal of neurology
              Type: main
ResultId 1